Drug Discovery & Development
Lessons learned help the cell and gene therapy industry deliver products to patients
On the second day of the Cell & Gene Meeting on the Mesa, Betty Woo, PhD, vice president and general manager of cell and gene therapy (CGT) at Thermo Fisher Scientific, led a workshop titled "Industrialization of Cell Therapy Manufacturing -- Lessons Learned From Biologics." ScienceBoard.net caught up with Woo following the workshop. Read More
How can the cell and gene therapy field industrialize collaboration?
Adlai Goldberg, the global life sciences digital, social, and commercial innovation leader at Ernst & Young, led a workshop on "Unlocking the Power of Collaboration to Fuel the Industry Transformation for Cell and Gene Therapies" at the 2021 Cell & Gene Meeting on the Mesa. Goldberg called on the cell and gene therapy industry to adopt a mindset of co-collaboration. Read More
5 takeaways from the Cell & Gene Meeting on the Mesa
In this final episode of our coverage from the 2021 Cell & Gene Meeting on the Mesa, hosted by the Alliance for Regenerative Medicine, ScienceBoard.net Editor-in-Chief, Samantha Black, PhD, discusses five takeaways from the event. Read More
Cardiovascular cell, gene therapy leaders discuss nascent field
The emerging field of cardiovascular cell and gene therapies shows great promise to significantly improve clinical outcomes, but it still faces key challenges, according to an October 13 plenary session at the Cell & Gene Meeting on the Mesa. Read More
Precision Advance aims to improve patient access to cell and gene therapy
Improving patient access to cell and gene therapy treatments is the goal of Precision Advance, an initiative of Precision Medicine Group. Precision Advance provides a set of interconnected services and personnel designed to help bring new therapies to market. Read More
Catching up with the Alliance for Regenerative Medicine at Cell & Gene Meeting on the Mesa
CARLSBAD, CA - What's going on at this week's Cell & Gene Meeting on the Mesa? ScienceBoard.net spoke with Stephen Majors, director of public affairs at the Alliance for Regenerative Medicine, who shared what's being discussed at this year's meeting. Read More
Tecartus becomes 1st CAR T-cell therapy to receive FDA approval for adults with ALL
Tecartus (brexucabtagene autoleucel), a CAR T-cell therapy, has gained approval from the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adult patients. Read More
AI drug development market projected to reach $5.1B by 2025
The world market for AI applications in drug development is projected to reach $5.1 billion by 2025, an increase of more than $3.6 billion from the market size in 2020. However, significant challenges are lurking ahead as the industry enters the next phase, according to Ulrik Kristensen, PhD, of Emersion Insights. Read More
AI model predicts oxygen needs of COVID-19 patients
Researchers have trained an artificial intelligence (AI) model to predict the future oxygen needs of symptomatic patients with COVID-19, according to a study published in Nature Medicine on September 15. Read More
5 ways social media can make drug development more patient-centered
Insights gleaned from analyzing social media can facilitate patient-centered drug development and help spur innovation in drug discovery, according to a paper published online recently in Drug Discovery Today. Read More
Conferences
Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter